ProCE Banner Activity

First-line Checkpoint Inhibitor Therapy in Metastatic NSCLC: A New Option for Our Patients

Clinical Thought
Checkpoint inhibitor therapy is now approved for newly diagnosed metastatic NSCLC. Naiyer Rizvi, MD, discusses the latest clinical data from ESMO 2016 supporting this landmark change in advanced NSCLC management.

Released: October 27, 2016

Expiration: October 26, 2017

No longer available for credit.

Share

Faculty

Naiyer Rizvi

Naiyer Rizvi, MD

Professor of Medicine
Price Chair of Thoracic Translational Oncology

Director of Thoracic Oncology
Director of Immuno-Oncology
Columbia University Medical Center
New York, New York

Provided by

Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

AbbVie

Celgene

Genentech Roche Virology

Lilly

Merck Oncology

Novartis Pharmaceuticals Corporation

Faculty Disclosure

Primary Author

Naiyer Rizvi, MD

Professor of Medicine
Price Chair of Thoracic Translational Oncology

Director of Thoracic Oncology
Director of Immuno-Oncology
Columbia University Medical Center
New York, New York

Naiyer Rizvi, MD, has disclosed that he has received consulting fees from AstraZeneca, Merck, Novartis, and Roche and has ownership interest in Gritstone Oncology.